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Objective: This study assessed preliminary results of the Ventana Fenestrated System (Endologix, Irvine, Calif) as an off-the-
shelf integrated device for juxtarenal aortic aneurysm (JAA) or pararenal aortic aneurysm (PAA) endovascular repair.
Methods: From November 2010 to April 2012, seven centers enrolled 31 patients with JAAs or PAAs in an international
clinical trial of the Ventana Fenestrated System. Clinical and laboratory evaluations were done predischarge and at
1 month, with continuing follow-up through 5 years. Core laboratory computed tomography imaging assessments were
performed at 1 month and at each subsequent follow-up.
Results: Patients (mean age, 73 years; 90% male) presented with mean aneurysm sac diameter of 6.0 cm. One patient with
a short, reversed tapered infra-superior mesenteric artery (SMA) neck was enrolled under a protocol waiver. Among the 31
patients, one of ﬁve Ventana device models was used to preserve main renal arteries, the SMA, and celiac arteries; 20 patients
(65%) received the same Ventana device (aligned fenestrations, 28-mm diameter). Median ﬂuoroscopy and procedure times
were 49 and 197 minutes, respectively; median hospital length of stay was 3.0 days. The 1-month clinical success rate was
94% (29 of 31), with no perioperative mortality. One intervention on day 26 was done to resolve limb kink/occlusion. A
type IA endoleak and renal occlusion secondary to procedural device damage led to a reintervention on day 52 and dialysis
at 5 months. During follow-up to 23 months, three non-aneurysm-related deaths occurred. No aneurysm rupture or
conversion to open repair has occurred. One late migration with endoleak and covered renal stent fracture/occlusion
occurred at 8 months in the patient with a short, reverse tapered infra-SMA neck performed under a protocol waiver, which
was managed successfully with bilateral renal bypasses and endovascular repair of the endoleak. Another patient underwent
late endovascular interventions to resolve bilateral renal stenosis.
Conclusions: The multicenter experience of the Ventana Fenestrated System supports its safety and early-term to midterm
effectiveness for the endovascular repair of JAAs and PAAs. This off-the-shelf integrated system permits endovascular
treatment of JAAs or PAAs; however, further expanded clinical experience and longer-term follow-up are needed to more
fully assess this device system. (J Vasc Surg 2013;58:1-9.)the Department of Surgery, University of California at Los Angeles
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://dx.doi.org/10.1016/j.jvs.2012.12.065Lower morbidity and mortality after endovascular
repair of abdominal aortic aneurysms has encouraged
the application of available device technology outside
of the manufacturer’s labeled indications.1,2 Whereas the
use of ancillary techniques to deal with unfavorable or
hostile proximal seal zones (eg, short, irregular, angulated,
thrombus-laden) has had reasonable early success, a higher
risk of adverse outcomes (eg, type IA or type III endoleak,
migration, rupture) has been reported in the midterm and
longer term.2,3 The goal of extending an endovascular
option for aneurysms with short or no infrarenal necks or
visceral artery involvement, or both, has encouraged the
development of more standardized techniques to preserve
visceral ﬂow, taking advantage of a seal zone in the more
proximal, usually healthier aorta below the superior mesen-
teric artery (SMA).
Essentially two approaches have evolved: chimney and
snorkel techniques involving the combination of covered1
Table I. Patient selection criteria
d Iliac/femoral artery access vessel diameter compatible with
delivery systems
d Renal arteries with length $13 mm and without signiﬁcant
occlusive disease (<70% stenosis)
d Absence of essential accessory renal artery (ie, one that
supplies >25% of the renal parenchyma on the preoperative
CT scan)
d Mural thrombus in suprarenal segment #5 mm in thickness
over #60% of circumference
d Infrarenal neck length <15 mm
d Nonaneurysmal proximal neck relative to the SMA with
length $15 mm, diameter 18 to 34 mm, and angle to the
aneurysm sac #60
d Renal arteries with reference diameters of 4 to 8 mm, that are
0 to 35 mm below the SMA and within each other 630 mm
(longitudinally) and 90 to 210 (clock face)
d Celiac artery-to-SMA angle #60 (clock face)
d SMA-to-aortoiliac bifurcation length $90 mm
d Common iliac artery diameter 10 to 23 mm with seal zone
length $15 mm
d Ability to preserve at least one hypogastric artery
d Fenestrated stent graft overlap with bifurcated stent graft
$3 cm
CT, Computed tomography; SMA, superior mesenteric artery.
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infrarenal endograft4-6 or customized devices using covered
stents through patient-speciﬁc main endograft fenestrations
to the visceral arteries.6-9 Intuitively, the latter seems prefer-
able because it may achieve a more predictable seal at the
endograftevisceral stent interface. Historically, the main
disadvantages of the fenestrated approach are that the
surgeon must design and create the endograft by altering
a commercially available device (time-consuming, quality-
control issues, liability) or it is custom-produced by the
manufacturer for the particular patient’s anatomy (delay in
treatment, cost). These limitations have naturally led to
the search for off-the-shelf endograft design platforms for
these more complex aneurysms.
The Ventana Fenestrated System (VFS) consists of an
integrated endovascular stent graft system deployed as
a proximal extension to the currently Food and Drug
Administration-approved AFX (Endologix, Irvine, Calif)
infrarenal endograft. A generous proximal scallop preserves
blood ﬂow to the SMA and celiac arteries. In situ movable
fenestrations with preloaded sheaths are used to place
covered stents into the renal arteries to complete aneurysm
exclusion. It has been designed as an off-the-shelf system for
the treatment of juxtarenal aortic aneurysms (JAAs) or para-
renal aortic aneurysms (PAAs).
We present the early-term to midterm results of a multi-
center clinical trial using the VFS for the management of
high-risk patients with JAAs or PAAs.
METHODS
Study design and patient selection. Seven interna-
tional centers with experience in infrarenal endovascular
aortic stent grafting, complex open surgical repair, and
visceral artery interventional techniques participated in
this trial. Each site obtained ethical approval for human
investigation and necessary government authorization,
and written patient informed consent was obtained. Preop-
eratively, a high-resolution, contrast-enhanced computed
tomography (CT) scan assessment of the descending
thoracic and abdominal aorta was conducted by an inde-
pendent core laboratory (Cleveland Clinic Foundation
Peripheral Vascular Core Lab, Cleveland, Ohio). An inde-
pendent physician reviewed the CT scan and core labora-
tory assessment, as well as angiography, if available, to
determine anatomical eligibility for enrollment.
Angiography was selectively done to assess the degree
of stenosis if a signiﬁcant renal artery lesion was seen on
the CT scan. Key considerations were quality of the prox-
imal infra-SMA neck (ie, <20% diameter change over the
most proximal 15-mm neck length without severe plaque
or thrombus) and renal arteries (ie, <70% ostial stenosis
with suitable diameter and length for covered stent place-
ment). Ankle-brachial index (ABI) and blood laboratory
evaluations, medical history, and physical examination
were performed. These baseline assessments were used to
determine patient suitability for enrollment (Table I).
Device description. The VFS consists of the commer-
cially available AFX 22- or 25-mm bifurcated stent graftseated at the aortoiliac bifurcation, the Ventana fenestrated
proximal extension stent graft, and Xpand (all Endologix)
balloon-expandable covered renal stents (Fig 1). All are
manufactured and packaged in individual catheter-based
delivery systems as ready-to-use, sterile medical devices.
The bifurcated stent graft is a unibody self-expanding
cobalt chromium alloy endostent with a multilayer
expanded polytetraﬂuoroethylene (ePTFE) graft that is
attached to the stent proximally and distally using surgical
suture. The Ventana stent graft has the same stent element
design as the bifurcated stent graft; it is continuous in the
proximal and distal sections, with anterior and posterior
stent elements connecting these segments (Fig 2). Its
multilayer ePTFE graft is a one-piece design attached to
the stent proximally and distally, incorporating an over-
sized midsection with two fenestrations. There is no stent
interference with the fenestrations (Fig 2). An ample prox-
imal 4-cm-length scallop encompasses the SMA and celiac
arteries, with sizes available to treat aortic diameters from
18 to 34 mm. The 28-mm-diameter distal segment
permits substantial overlap ($3 cm) with the bifurcated
device body. Radiopaque markers identify the scallop
margins, center, and circumference of each fenestration.
The fenestrations are expandable from their nominal
3-mm-diameter to 10 mm and are movable in situ longi-
tudinally and circumferentially to accommodate renal
arteries spaced 630 mm longitudinally and 90 to 210
(clock face).
The 22F proﬁle delivery system incorporates preloaded
guide sheaths transfenestration for simpliﬁed renal artery
cannulation and covered renal stent delivery. The Xpand
device is a balloon-expandable, multilayer ePTFE-covered
cobalt chromium alloy stent premounted on a 115-cm-
length nylon balloon catheter that is compatible with
Fig 1. The Ventana Implant. Note the bifurcated unibody stent graft anatomically ﬁxed at the aortic bifurcation, the
Ventana fenestrated proximal extension stent graft, and the balloon-expanded covered renal stents.
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The proximal segment of the covered stent, available in
18-, 25-, or 35-mm lengths, is designed to be ﬂared in
the aorta after implant across the fenestration. Selective
angiographic catheters that have various tip conﬁgurations
with 120-cm length, compatible with the Ventana delivery
system guide sheaths, are used.
Deﬁnitions. JAA is deﬁned as an aneurysm encroach-
ing upon but not involving the renal arteries. PAA is
deﬁned as an aneurysm involving one or both of the renal
arteries. Renal failure is deﬁned as serum creatinine increase
>0.5 mg/dL on two consecutive assessments or need for
temporary or permanent dialysis. Renal dysfunction is
deﬁned as reduction in estimated glomerular ﬁltration
rate (eGFR) >30% from baseline. Major adverse events
(MAE) include all-cause mortality, bowel ischemia,
myocardial infarction, paraplegia, renal failure, respiratory
complication, stroke, and blood loss $1000 mL. Proce-
dure technical success was deﬁned as successful device
delivery and deployment, with resulting patency of all
visceral arteries and no type I or III endoleak at the
completion of the procedure. The primary end point,
treatment success, is deﬁned as successful device delivery
and deployment with resulting patency of all visceral
arteries and absence of type I or III endoleak at 1 month.
Implant procedures. Each principal investigator
underwent didactic training and performed in vitro implants
using the integrated VFS in a pressurized ﬂow model of
a replica juxtarenal aneurysmal anatomy with only ﬂuoro-
scopic visualization. A trained proctor attended each case.
Device delivery and deployment has been previously
described.10 The implantation is performed through
femoral artery access or iliac conduit, as indicated. Brieﬂy,
after bifurcated device anatomic ﬁxation, the VFS isadvanced ipsilaterally over the stiff 0.035-inch guidewire.
Outer sheath retraction exposes the precannulated renal
guide sheaths. Importantly, the proximal and distal stent
graft segments remain fully constrained within the delivery
system, maximizing maneuverability within the visceral
segment (Fig 3). Cannulation of the renal arteries occurs at
this time using physician-selected angiographic catheters
and guidewires introduced through the transfenestration
guide sheaths. Ventana deployment proximally then distally
is performed. Integrated pushers may be used to advance
the fenestrations to or into the renal ostia. The covered renal
stents are advanced through the guide sheaths and into the
renal arteries, where they are deployed and then ﬂared in the
aorta with a separate 10-mm balloon.
Follow-up evaluations. Before hospital discharge,
patients underwent a clinical and laboratory examination.
Follow-up is at 1 month, 6 months, 1 year, and annually
to 5 years. History and physical examination, blood labo-
ratory evaluations, ABI determinations, and contrast-
enhanced CT scans are conducted at each visit. Duplex
ultrasound imaging is performed at site discretion. Core
laboratory evaluation of the CT scans is the basis for device
performance and efﬁcacy determinations.
Data analysis. Baseline and procedural continuous,
ordinal, and categoric variables are presented descriptively.
An independent Clinical Events Committee adjudicates
adverse events for analysis, and oversight reviews by an inde-
pendent Data Safety Monitoring Board occur periodically.
Early (#30 days) and late (>30 days) MAEs, endoleak,
and aneurysm data are presented descriptively. Primary
end point analysis is done using the exact binomial distribu-
tion. Statistical signiﬁcance is considered for P < .05. Anal-
yses are performed using SAS 9.1 software (SAS Institute,
Cary, NC).
Fig 2. Ex vivo images show front (left) and side views (right) of
the Ventana stent graft and the ﬂared renal stent graftefenestration
interface (bottom).
Fig 3. Angiographic image shows renal cannulation. The Ventana
fenestrated proximal extension stent graft is constrained, maxi-
mizing maneuverability within the visceral segment.
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Enrollment and procedural outcomes. Fifty-one
patients were consented and screened, with 31 found
eligible and enrolled between November 2010 and April
2012, which includes a 6-month period while several
sites were awaiting government approvals. Primary reasons
for screen failure included inadequate infra-SMA neck
length, inadequately sized access vessels, and unsuitable
renal artery diameter or length. One patient was excluded
because the screening showed a long (>35 mm) distance
from the SMA to the renal artery. One patient with a short
(9-mm length), reverse tapered infra-SMA proximal neck
was accepted for enrollment under a protocol waiver.
Table II summarizes the preoperative patient demo-
graphics, risk factors, and baseline aneurysm characteristics.
Patients were a mean age of 73 years, and 91% were men.
Medical history and risk factors were typical of this pop-
ulation with aneurysmal disease.Five Ventana models were used: 30 patients received
the device with aligned fenestrations, with 20 receiving
the 28-mm device. One patient whose renal arteries were
longitudinally spaced at 18 mm received the 32-mm device
with the left superior fenestration. The Core Laboratory
characterized the infra-SMA neck shape as funnel or reverse
funnel in 26% of patients, with all but one having <20%
diameter change over the ﬁrst 15-mm infra-SMA neck
length. The visceral morphology of the 31 patients is
shown in Fig 4, illustrating the range of anatomy treated.
Intraoperative angiography veriﬁed that in each patient,
the Ventana scallop was placed accurately below and about
the SMA and celiac arteries with no obstruction. The ﬁrst
ﬁve patients enrolled received Advanta V12 covered
renal stents (Atrium Medical, Hudson, NH). Preplanned
concomitant procedures include stenting of the SMA
(n ¼ 1), bypass of an external iliac artery to the hypogastric
artery (n ¼ 1), conduit placement due to inadequate access
vessel size (n ¼ 4), and unilateral hypogastric artery embo-
lization (n ¼ 6).
Technical success was achieved in 30 of 31 patients
(97%). Procedural results, including complications and
clinical utility outcomes, are summarized in Table III. In
one patient, the device implants were completed success-
fully. At ﬁnal angiography, the physician was uncertain
whether an endoleak was present, and elected to balloon
model the implant. Renal sheaths had been removed, and
renal artery reaccess was attempted but could not be
gained. Inadvertent compression of the implanted covered
renal stents occurred during balloon modeling of the prox-
imal segment. Upon ﬁnal angiography, partial occlusion
of the left covered renal stent and malpositioning of the
Ventana device appeared to result in an incomplete seal
at the proximal segment.
In another patient, procedure time was prolonged
(566 min) secondary to signiﬁcant renal ostial stenosis
Table II. Baseline demographics and risk factors
Characteristic
No. (%) or
mean 6 SD (range)
(n ¼ 31)
Demographics
Male sex 28 (91)
Age, years 73 6 7.5 (55-85)
GFR, mL/mina 68 6 21 (42-125)
Risk factors
Arrhythmia 7 (23)
Cancer 9 (29)
Coronary artery disease 10 (32)
Chronic obstructive pulmonary disease 6 (19)
Diabetes 6 (19)
Family history of AAA 1 (3.2)
Gastrointestinal abnormalityb 6 (19)
Hypertension 21 (68)
Hypercholesterolemia 25 (82)
Peripheral arterial disease 3 (9.7)
Prior abdominal surgery 7 (22)
Prior myocardial infarction 4 (13)
Prior CABG or PCI 6 (19)
Smoking (ever) 16 (52)
Aneurysm characteristics
Aneurysm sac diameter, cm 6.0 6 0.9 (4.9-10)
Irregular infra-SMA neckc 8 (26)
Infra-SMA neck diameter, mm 25 6 2.8 (21-30)
Infra-SMA neck length, mm 27 6 11 (9-35)
Infra-renal neck length, mm 6.9 6 3.4 (0-14)
Angulation,
Suprarenal aorta to renal artery 57 6 11 (42-83)
Infra-SMA neck to sac 36 6 12 (20-53)
SMA to celiac artery (clock face) 14 6 9.0 (0.8-30)
SMA to aortic bifurcation length, mm 145 6 17 (122-186)
AAA, Abdominal aortic aneurysm; CABG, coronary artery bypass grafting;
GFR, glomerular ﬁltration rate; PCI, percutaneous coronary intervention;
SD, standard deviation; SMA, superior mesenteric artery.
aEstimated by the Cockroft-Gault equation.
bIncludes stomach ulcer, Crohn disease, ulcerative colitis, and nonspeciﬁc
irritable bowel conditions.
cFunnel or reverse taper, deﬁned as length with 11% to 20% change in neck
diameter.
Fig 4. Visceral morphology of the 31 study patients. A, Distri-
bution of centerline lengths: superior mesenteric artery (SMA) to
left renal artery (LRA); SMA to right renal artery (RRA); and
LRA to RRA. B,Distribution of clock face angle between the LRA
and RRA.
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 1 Quiñones-Baldrich et al 5(w80%) not recognized on the preoperative CT scan.
Renal stent placement was eventually accomplished to
address the stenosis. The Ventana implant was then
successfully delivered and deployed. Experience with this
patient led to a protocol revision requiring angiographic
evaluation of renal artery stenosis when suspected on CT
scan before inclusion in the trial.
Complete 1-month follow-up data are available for all
31 patients. After 30 days to 6 months, three patients
died; 6-month data are available on the 28 survivors.
Longer-term follow-up is available to a maximum of
23 months in 11 patients. The mean follow-up is 1.3 years.
Primary end point results. Within 1 month, one iliac
occlusion and one renal occlusion with endoleak occurred,
yielding a treatment success rate of 94% (29 of 31; P ¼ .01,
binomial distribution). The former was a right external iliac
artery occlusion due to a kink in the bifurcated device right
limb, and the patient underwent successful femoral-to-
femoral bypass on day 26. The renal occlusion occurred
in the patient with intraoperative ballooning over theunprotected covered renal stents. Renal occlusion and
ischemia and endoleak of unknown origin were reported.
Onyx liquid (Covidien, Irvine, Calif) embolic sac emboli-
zation via catheter introduction behind the Ventana scallop
was performed on day 52 to resolve the endoleak, and no
renal intervention was performed.
Mortality and MAEs. No early deaths occurred. After
30 days and within 6 months, three non-aneurysm-related
deaths occurred secondary to a witnessed accidental fall,
left parietal intracerebral hemorrhage in a patient with
chronic atrial ﬁbrillation (both with autopsy), and cardio-
pulmonary arrest secondary to pre-existing chronic
obstructive pulmonary disease. All were adjudicated as
non-aneurysm-related.
Pneumonia on postoperative day 12 in one patient was
treated medically without sequelae. Four patients (13%)
were observed procedurally with blood loss $1000 mL
due to access vessel injury or to ﬁrst-generation delivery
Table III. Procedural and in-hospital outcomes
Parameter
No. (%) or
median (range)
(n ¼ 31)
Anesthesia type
General 26 (84)
Regional 5 (16)
Ventana device usage
Aligned fenestrations 30 (97)
24 mm 4 (13)
28 mm 20 (65)
32 mm 5 (16)
36 mm 1 (3.2)
Offset fenestrations (32 mm) 1 (3.2)
Procedural complicationsa
Access vessel repair 2 (6.5)
Access site hematoma 3 (9.7)
Minor renal artery dissection angioplasty 1 (3.2)
Clinical utility outcomesb
Renal cannulation time, min 18 (8-92)
Endovascular device time, min 97 (71-490)
Total procedure time, min 197 (115-566)
Estimated blood loss, mL 500 (49-1500)
Fluoroscopy time, min 49 (27-104)
Contrast volume, mL 189 (50-500)
Time to hospital discharge 3.0 (2-9)
aAll complications were resolved.
bRenal cannulation time is deﬁned as the time from bifurcated delivery
system introduction to cannulation completion of both renal arteries.
Endovascular device time is deﬁned as the time from bifurcated delivery
system introduction to Ventana delivery system removal. Total procedure
time is the skin-to-skin time.
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are reported in three patients. The patient with procedural
covered renal stent damage and compression became
dialysis-dependent at 5 months, and a myocardial infarction
at 1 month subsequently was treated with percutaneous
coronary intervention. Pneumonia with concomitant
congestive heart failure was treated medically in another
patient at 6 months. Lastly, the patient enrolled with a short
infra-SMA neck length presented in renal failure with bilat-
eral renal occlusion and covered renal stent fractures at
8 months, and temporary dialysis was initiated to maintain
renal function. Extranatomic renal bypasses were per-
formed successfully, with restoration of renal function.
Other treatment effectiveness evaluations
Renal function. Preoperatively, eGFRwas<60mL/min
in 15 of 31 patients (48%) and $60 mL/min in 16 (52%).
Only one patient in the latter group was observed with renal
dysfunction at 1 month, attributed to covered renal stent
compression procedurally. Paired comparisons of eGFR in
late follow-up vs baseline reveals similar results at 6 months
(59 6 21 vs 66 6 19 mL/min; n ¼ 28; P ¼ .23) and
12 months (606 22 vs 576 14 mL/min; n¼ 10; P¼ .72).
The Core Laboratory has not identiﬁed any renal infarcts
among the cohort.
Visceral artery patency. Preoperatively, four patients
had a unilateral renal artery stenosis; no stenosis was
observed at 1 month in these patients. Visceral arterypatency was 98% at 1 month. One patient with a procedural
complication described previously, who did not have a pre-
existing renal stenosis, was observed with severe renal
stenosis at 1 month, with >30% reduction in eGFR.
Secondary procedures. In the patient in whom inad-
vertent implant damage occurred procedurally, liquid
embolic embolization of the sac via catheter introduction
at the scallop was performed on day 52 postoperatively.
Intervention for late renal artery stenosis was reported in
two patients. One received a 5-mm Advanta V12 covered
renal stent, and distal stenoses developed and was treated
on day 235 with an 8-mm self-expanding stent; in-stent
stenosis was later treated on day 383. In another patient,
who received a 6-mm covered renal stent and a self-
expanding stent due to severe renal artery angulation, in-
stent stenosis with occlusion at 5 months was treated
with lysis, angioplasty, and stent placement. One late
implant failure occurred at 8 months in the patient with
a short, reverse-tapered infra-SMA neck (protocol waiver).
The patient presented in renal failure, and temporary
dialysis was initiated. Lateral device movement, bilateral
covered renal stent fracture, and endoleak between the
left covered renal stent and fenestration were treated with
renal bypasses and extension placement across the existing
aortic devices to resolve the endoleak.
Endoleaks. Eight patients (26%) were observed with
type II endoleak at 1 month. Two patients were found
with endoleak of unknown origin: one with inadvertent
damage to the implant procedurally (possible type II or
type IA) and one with an inferior mesenteric artery
occluded at its origin and reconstituted distally (possible
type II). No intervention was performed. No type I, type
III, or type IV endoleaks have been observed through
current follow-up in suitably selected patients (this of
course excludes the patient enrolled under the protocol
waiver). Type II endoleak was observed in ﬁve patients at
6 months and persisted in 2 patients at 1 year.
Device stability and aneurysm sac morphology.
Among the 30 patients enrolled with suitable anatomy, no
migration has been reported by the Core Laboratory
through current follow-up. All SMA and celiac arteries
remain preserved. Aneurysm sac diameters were stable at
6 months (5.8 6 0.7 cm) and 1 year (5.6 6 0.3 cm), with
no sac expansion.
DISCUSSION
Understandably, an attempt has been made to extend
the beneﬁts of endovascular repair to patients with anatomy
outside of labeled indications, recognizing that, even in
these cases, beneﬁt may be derived. Unfortunately, ancil-
lary techniques are affecting repair durability, increasing
the risk of late adverse outcomes compared with patients
treated within the instructions for use.11
Two approaches have been advocated for endovascular
repair of aneurysms with short infrarenal necks or JAAs.
The chimney and snorkel technique ﬁrst described by
Greenberg et al12 uses available devices by creating parallel
channels with covered stents to maintain visceral perfusion.
Table IV. Early major adverse events after juxtarenal
aortic aneurysm (JAA) and pararenal aortic aneurysm
(PAA) endografting, infrarenal endografting, or open repair
Major adverse eventa
Ventana
cohort
(n ¼ 31),
No. (%)
Infrarenal
test
(n ¼ 192),
No. (%)
Open surgical
control
(n ¼ 66),
No. (%)
Patients with $1 event 5 (16) 16 (8.3) 44 (67)
Death 0 2 (1.0) 4 (6.1)
Bowel ischemia 0 0 6 (9.1)
Myocardial infarction 0 3 (1.5) 5 (7.6)
Paraplegia 0 0 0
Renal failure 0 2 (1.0) 6 (9.1)
Respiratory failure 1 (3.2) 2 (1.0) 5 (7.6)
Stroke 0 0 1 (1.5)
Blood loss $1000 mL 4 (13) 11 (5.7) 38 (58)
aResults shown as number of patients with event (% of total in group).
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created by the stent graft outside the main endograft is
reduced by creating two chimneys with a 20-mm seal
zone length.4 Bruen et al4 compared 21 chimney-treated
patients with 21 anatomically matched open surgery
patients. Operative mortality (4.8%) was similar. Acute renal
dysfunction was high in the endovascular group (29%) due
to planned renal artery coverage in some patients. Nonethe-
less, permanent dialysis occurred only in open surgery
patients (9.5%). Others reported their 10.7-month experi-
ence with the chimney technique in 28 consecutive JAA
patients. Complications included permanent dialysis (7.1%),
type I or III endoleak (14%), and one occlusion (3.5%).13
Although a chimney technique may be an appealing alterna-
tive for high-risk patients not suitable for standard endovas-
cular JAA repair, its off-label nature, need for brachial
access, and unclear long-term durability has limited wide-
spread adoption.
The fenestrations in patient-customized devices may be
a reinforced opening or a short branch intended to lengthen
the proximal aortic endograft-branch stent seal zone.14
Surgeon-modiﬁed devices start with a partially deployed
commercial endograft that is modiﬁed on a back table while
the patient is being prepared for surgery. Once prepared,
the modiﬁed device is reloaded into its delivery system.
Great care must be taken to avoid damage to the device
or subsequent patient injury during attempted delivery,
deployment, and implant. Although technically challenging,
several centers have reported acceptable early-term to
midterm results with this approach.7,15,16 The disadvan-
tages of this surgeon-modiﬁed graft approach are that crea-
tion of the device is time-consuming and presents quality
control challenges. Reimbursement for these procedures is
a nonresolved issue and may limit the ability of many insti-
tutions to sustain the effort. The main disadvantage of
commercially customized devices is the device planning
and production time (w8 weeks) along with an estimated
risk of interval rupture of 1.1% to 3.8%, depending on aneu-
rysm size.17 Both procedures are technically demanding,
requiring advanced visceral interventional skills and
experience.
In their review of custom fenestrated endografting in
629 PAAs, Linsen et al18 determined a 90% technical
success rate with 2.1% early mortality. Pooled estimates of
visceral artery occlusion, renal impairment, and secondary
intervention were 7%, 22%, and 18%, respectively.
Donas et al19 recently reported their experience with
90 consecutive JAA patients, of whom 31 were treated
with open surgery, 29 with custom fenestrated endograft-
ing, and 30 with a chimney technique. Among the custom
group, 12 Palmaz bridging stents (Cordis, Miami Lakes,
Fla) were required to achieve seal. Early mortality was 0%
in the endovascular groups and 6.4% in the open surgery
group. Permanent hemodialysis was required in 6.5% of
the open surgery group.
Coscas et al20 evaluated 50 consecutive JAA patients, of
whom 38 were treated with a custom fenestrated or
branched endograft and 12 with a chimney technique. Earlymortality was 8%. Higher renal complications occurred in
the chimney group (25% vs 13% with >50% increase in
serum creatinine; 25% vs 8% renal infarction). Type I or
III endoleak was 7.9% in the fenestrated group and 25% in
the chimney group. The authors note that endoleak is
frequent after these more complex approaches and is difﬁ-
cult to repair, particularly if in the proximal segment.
In our experience among 31 patients treated at seven
international centers, the VFS accommodated a wide
range of anatomies consistent with the design intent.
The ability to perform renal cannulation while the Ventana
stent graft remains fully constrained, in addition to incor-
porated preloaded transfenestration guiding sheaths, are
signiﬁcant differentiating design features that simplify renal
cannulation. In our experience, 97% of repairs were done
with aligned fenestrations and the single remaining case
was with a left superior fenestration design with renal
arteries longitudinally spaced by 18 mm. Two-thirds of
the patients were treated with the same device (aligned
fenestrations, 28-mm diameter).
The incidence of early MAEs was 16%, with no perio-
perative deaths. This rate is twice that observed in the test
arm of the original Powerlink (Endologix) infrarenal
endografting trial (Table IV)21 but is signiﬁcantly lower
than the 67% observed in that trial’s surgical control arm
(P < .01) involving patients with JAAs (76%), PAAs
(21%), or suprarenal aneurysms (3.0%). Delivery system
improvements have been made to internalize valves
without physician manipulation and thus reduce blood
loss due to delivery catheter valve damage (clinical use
initiated in 2012). The incidence of limb occlusion of
3.2% was similar to the 1.3% observed in the infrarenal
anatomic ﬁxation trial.21 Two patients required permanent
or temporary dialysis due to complications leading to fail-
ures that were potentially avoidable. Visceral artery
patency was 98% in the early period and 94% to date in
late follow-up.
The importance of adherence to anatomic guidelines is
illustrated by the single major complication in a patient
with, in retrospect, an unsuitable proximal infra-SMA
Table V. Comparison of outcomes with published results of open and endovascular repair of juxtarenal aortic aneurysms
(JAAs) or pararenal aortic aneurysms (PAAs)
Reference Type No.
Follow-up,
mean
months
Sac
diameter,
mean mm
Infrarenal
neck
length,
mean mm
Technical
success,a
% Pts
30-day
death,
%
Late
death,
%
Target vessels
incorporated
and patency,
% vessels
Post-op
renal
dysfunction,b
% Pts
Late
secondary
procedures,
% Pts
Sarac,22 2002 OSR 138 1 64 NR NR 5.10 — — 22 NR
Knott,23 2008 OSR 126 1 NR NR NR 0.80 — — 18 NR
Semmens,24 2006 CFE 58 17 NR NR 83 3.40 10 116 (91) 9.50 24
Chisci,25 2009 CFE 52 20 60 7.5 NR 5.70 NR NR 14 12
Greenberg,8 2009 CFE 30 24 61 9.2 100 0 6.70 77 (92) 20 23
Amiot,9 2010 CFE 134 15 56 NR 99 2.20 9.10 403 (97) 10 12
Ventana study VEN 31 9 60 6.9 97 0 9.30 124 (94) 9.70 9.70
CFE, Custom fenestrated endograft; eGFR, estimated glomerular ﬁltration rate; NR, not reported; OSR, open surgical repair; VEN, Ventana system.
aAs reported by the authors. One Ventana procedure with unintended covered renal stent compression leading to renal dysfunction at 1 month is considered
a technical failure.
bAs reported by the authors. OSR reports provide the rates of renal impairment or failure; Ref 24 provides the rate of target vessel loss (% vessels); Ref 25
provides the rate of permanent renal impairment (% patients); Ref 8 provides the incidence of renal stenosis or occlusion necessitating intervention; Ref 9
provides the rate of eGFR deterioration inclusive of permanent or temporary dialysis. The present report provides the rate of renal dysfunction (>30%
reduction in eGFR) inclusive of permanent or temporary dialysis.
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Root cause analysis determined this anatomy involving
a short, reverse tapered infra-SMA neck led to device
compromise. The observance of anatomic selection criteria
and sizing recommendations is likely to be more critical
as the complexity of endovascular repair increases with
these more sophisticated devices.
These results with the VFS compare well with pub-
lished outcomes of open or endovascular repair of JAAs
(Table V).8,9,22-25 Because these studies were performed
using different patient selection criteria, procedures, and
follow-up methods and durations, more speciﬁc compari-
sons are not appropriate.
Study limitations include the small cohort size and the
available follow-up to a mean of 1.3 years. There was also
possible selection bias, given 31 of 51 patients were
selected based on inclusion and exclusion criteria and the
opinion of a single independent physician who analyzed
anatomic suitability for inclusion in the trial. Certainly,
additional independent reviewers potentially could inﬂu-
ence the ﬁnal decision. These patients continue to be eval-
uated, according to the trial protocol, with clinical and
imaging studies yearly. Lastly, this study was conducted
in high-volume centers of excellence with experienced
physicians, and thus, the results need to be considered in
that context.
CONCLUSIONS
The Ventana fenestrated graft system is safe and
appears effective in suitable patients with JAAs or PAAs.
Further clinical experience and longer-term follow-up are
justiﬁed and needed to establish long-term performance
of this system.
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Submitted Oct 6, 2012; accepted Dec 14, 2012.DISCUSSIONDr Timothy A. M. Chuter (San Francisco, Calif). In the
interest of full disclosure, I have to let you know that I licensed
all my patents in this ﬁeld to Cook, the manufacturer of a
competing fenestrated stent graft.
Based on the short-term results of this study, I would have to say
that the Ventana worked pretty much as intended, barring the occa-
sional technicalmisadventure.That’s tobe expected for three reasons.
First, when was the last time anyone saw unfavorable short-term
results in an industry-sponsored study? Second, many of the Venta-
na’s featuresdmodular construction, staged deployment, catheter-
guided expansion, stent-secured alignmentdhave already been
widely tested and reﬁned in an extensive clinical experience going
back 14 years. Third, candidates for inclusion in the current study
were subjected to a rigorous selection process; for example, all the
on-protocol patients in this study had some sort of infrarenal neck.
The most impressive feature of the Ventana stent graft is its
versatility, which is attributable to the mobility of fenestrations in
a baggy unattached segment of graft fabric. Not that this is a new
idea: prototypes of such a stent graft have been around for more
than a decade. They never found their way into clinical use until
now, partly because weworried that a baggy graft would not protect
the surrounding aorta from dilatation, leading to secondary endo-
leak and stent graft migration. As illustrated by the sole off-protocol
case, the Ventana stent graft is highly unstable in the presence of
a dilated pararenal aorta. So I have just one question: What do
you think about adding some barbs to the proximal stent?Dr William J. Quiñones-Baldrich. The early results of the
Ventana clinical trial herein presented are indeed encouraging. I
agree that these are short-term results in a highly selected group
of patients. Certainly, this is true of all initial clinical trials of the
new devices. The exciting aspect of this particular device is its
unique feature of movable fenestrations, which increases the appli-
cability of a single graft to a wide range of anatomic variance. It is
important to note, however, that the baggy or unsupported
portion of the device does not allow unlimited expansion; thus,
if any dilation of the aorta were to occur, it would be eventually
restricted.
I disagree with the characterization that this device is highly
unstable in the presence of a dilated pararenal aorta. The single
patient done under a protocol waiver had a proximal neck that
was outside the range treatable with the largest device. It is no
surprise that the graft did migrate in that patient. In response to
your question, the experience to date with the Endologix infrare-
nal device suggests that anatomic ﬁxation and the overlap of the
proximal extension provide enough support to avoid migration.
The Ventana proximal extension has, in addition, a suprasuperior
mesenteric artery stent and two renal grafts through the fenestra-
tions, which should provide additional ﬁxation. Unless further
experience suggests that these elements are insufﬁcient, the addi-
tional barbs do not seem necessary. I would like to thank Dr
Chuter for his comments and the Western Vascular Society for
the opportunity to present this study.
